Navigation Links
Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2012
Date:7/25/2012

guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms  "could," "believe,"  "outlook," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of global economic conditions; the impact of  the 2010 federal health care legislation (including excise taxes on medical devices) and any further health care reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges associated with the successful commercialization of the company's particle therapy business; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future eve
'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
2. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
3. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
4. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
5. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. PhytoSPHERE Systems, a Medical Marijuana Inc Portfolio Company, to Bring Production Facilities to Europe through Canipa Holdings.
9. New White Paper, "Five Biggest Myths about Medical Products Outsourcing," Finds OEMs Concerns are Often Unfounded
10. Winner Medical Enters into Definitive Merger Agreement with Winner Holding Limited
11. No Medical Degree Necessary: An Easy Guide to Understanding Your Probiotic Supplement Label
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Cardiologists at Henry Ford ... stroke in patients with an irregular heartbeat. With ... Henry Ford is able to add another option ... fibrillation, which affects the heart,s ability to pump. ... and first-ever commercial Watchman implant at a non-clinical trial ...
(Date:4/21/2015)... -- According to a new market ... Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), ... Contamination, Adventitious Agents) - Global Forecast to 2019", ... Market was valued at $1,758.69 Million in 2014. ... CAGR of 12.23% to reach $3,130.85 Million in ...
(Date:4/21/2015)... -- Seattle Children,s announced today that 20 of 22 ... genetically reprogrammed T cells to treat relapsed acute lymphoblastic ... sensitive tests designed to detect minute amounts of cancer ... included children with very high tumor burdens as well ... "These results are extremely encouraging," said ...
Breaking Medicine Technology:Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 2Biologics Safety Testing Market Worth $3,130.85 Million by 2019 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 4Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 2Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 3
(Date:4/21/2015)... 2015 Carinsurancehints.com has released a new ... their impact on auto insurance prices . ... insurance prices. Clients should review their insurance options before ... bought under several forms. Some of the popular policies ... can compare online rates and find the best prices ...
(Date:4/21/2015)... On April 8th, 2015, Choices Recovery sponsored ... world famous Avalon Hollywood. Organized by Debbie Durkin, Los ... and film, the EcoLuxe Lounge is a premier red ... and festivals throughout the year. A gathering of some ... conscious products and services, this daylong event is attended ...
(Date:4/21/2015)... Edward Avalos, USDA Under Secretary for Marketing and ... the California Department of Food and Agriculture, have been ... Conference: The Future of Local Food, conference organizers announced ... known experts intensifies an already strong line-up of sustainable ... to speak at the June 11-13 event. ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 The ... Citrate Industry is a professional and in-depth study ... Sodium Citrate Market with a focus on ... in the sodium citrate market research are Cargill, ... Natural Biological, Cofco Biochemical, Capchem, Lianyungang Mupro Fi, ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Respected ... PACS® strategy , Visage Imaging Inc. (“Visage”), ... PME), has signed a seven-year contract with University ... in Northern Florida. The deal furthers the penetration ... hospital space, a key area of the North American ...
Breaking Medicine News(10 mins):Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4
... ... be a profitable 2010, the new Wella SP range is set to raise the ... ... hair company in the world, Wella is at the forefront of hairdressing innovation. The introduction ...
... ... struggle to find the balance between investing in the necessary internal resources to implement ... for a dozen online tactics, and identifies where companies are using each tactic in ... ...
... ... of the most common negative patterns in a relationship. Angry individuals may be aware of ... Path.com. , ... (PRWEB) February 1, 2010 -- Personal Power Path announces the launch of an anger management ...
... , Feb. 1 /PRNewswire / -- Ervin Cohen ... announced today that David Bricker , Of Counsel to ... clients last Friday, January 29, 2010 , in a medical malpractice ... Hopp of the Riverside Superior Court and a jury panel of 12. ...
... , BIRMINGHAM, Ala. , Feb. 1 ... Jon P. Stonehouse , President and Chief Executive Officer of BioCryst, plans ... forodesine and BCX4208 at the 12 th Annual BIO CEO ... at 10:30 a.m. Eastern Time . , Links to a ...
... contrast agent gadolinium during magnetic resonance imaging (MRI) for ... metastases, according to a new study published online February ... Institute . Gadolinium-enhanced MRI is primarily used to visualize ... and evaluate lymph node metastases. In light of this ...
Cached Medicine News:Health News:ckwrites.com Releases Report On Creating Online Marketing Tactics 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 3Health News:BioCryst To Present At 12th Annual BIO CEO & Investor Conference 2Health News:News brief: Contrast agent with MRI improves detection of lymph nodes metastases 2
The GelAir™ dryer is a component of the GelAir drying system. Supplied as a 230 V, 50 Hz gel drying oven....
... The PRO6000 power supply is ... power supply product offering. It ... and genomic electrophoresis. This product ... proteomic applications such as microAmp ...
... Operating as a constant voltage power supply, the ... knob and hilo range switch control the output, ... to 250 volts. One, two-position switch toggles the ... output current. The 105 is equipped with an ...
... The 250-90 low voltage electrophoresis power supply ... 500 milliamps and 125 watts. This product operates ... continuously variable output. The 250-90 automatically crosses over ... when a preset limit is reached. ...
Medicine Products: